

**Amendments to the Claims:**

This listing of claims will replace all prior versions and listings of claims in the application.

**Listing of Claims:**

1. (Currently Amended) A method of ameliorating symptoms associated with the growth of bone metastasized cancer or bone-originated cancer, comprising administering to an individual in need thereof a medicament comprising an amount of a parathyroid hormone-PTH receptor agonist effective to ~~reduce bone loss, reduce bone fracturing, and/or reduce pain;~~  
wherein said agonist comprises at least 25 amino acids and comprises at least 29% identity with SEQ ID NO: 1;  
wherein said agonist comprises an activation domain comprising amino acid sequence X1-V-S-E-X2-Q-X3, wherein X1 is selected from S or A, X2 is selected from I or H, and wherein X3 is selected from L or F; and  
wherein said agonist comprises an receptor binding domain comprising amino acid sequence L-X4-X5-X6-X7-X8-X9-X10-X11-X12-X13, wherein X4 is selected from R, H, or E, wherein X5 is selected from K, H, or Aib, wherein X6 is selected from K or L, wherein X7 is selected from I or L, wherein X8 is selected from A, Q, or E, wherein X9 is selected from D, E, K, or L, wherein X10 is selected from V, I, or L, wherein X11 is selected from H or Thi, wherein X12 is selected from N or T, wherein X13 is selected from F, A, or Y.
2. (Withdrawn) The method according to claim 1, wherein said amount is effective to reduce pain.
3. (Currently Amended) The method according to claim 1, wherein said parathyroid hormone-PTH receptor agonist is PTH or an analogue thereof.
4. (Currently Amended) The method according to claim 3, wherein said parathyroid hormone-PTH or an analogue thereof is parathyroid hormone-PTH (1-34).

5. (Currently Amended) The method according to claim 1, wherein said parathyroid hormone-PTH receptor agonist is parathyroid hormone-related protein or an analogue thereof.

6. (Previously presented) The method according to claim 1, wherein said individual has bone metastasized cancer.

7. (Previously presented) The method according to claim 6, wherein said bone metastasized cancer is breast cancer, prostate cancer, lung cancer, kidney cancer, ~~or~~ thyroid cancer or myeloma.

8. (Previously presented) The method according to claim 1, wherein said individual has bone-originated cancer.

9. (Previously presented) The method according to claim 1, wherein said bone originated cancer is sarcoma.

10. (Currently amended) The method according to claim 1, wherein the amount of the parathyroid hormone-PTH receptor agonist is from 0.1 to 1000 micrograms.

11. (Currently amended) The method according to claim 10, wherein the amount of the parathyroid hormone-PTH receptor agonist is from 20 to 200 micrograms.

12. (Currently Amended) The method according to claim 3, wherein said parathyroid hormone-PTH or an analogue thereof is teriparatide acetate.

13. (Withdrawn) A medicament for ameliorating symptoms associated with the growth of bone metastasized cancer or bone-originated cancer, comprising an amount of a PTH receptor agonist effective to reduce bone loss, reduce bone fracturing, and/or reduce pain in an individual in need thereof.

14. (Withdrawn) The medicament according to claim 13, wherein said amount is effective to reduce pain.

15. (Withdrawn) The medicament according to claim 13, wherein said PTH receptor agonist is PTH or an analogue thereof.

16. (Withdrawn) The medicament according to claim 15, wherein said PTH or an analogue thereof is PTH(1-34).

17. (Withdrawn) The medicament according to claim 15, wherein said PTH or an analogue thereof is teriparatide acetate.

18. (Withdrawn) The medicament according to claim 13, wherein said PTH receptor agonist is parathyroid hormone-related protein or an analogue thereof.

19. (Withdrawn) The medicament according to claim 13, comprising from 0.1 to 1000 micrograms of the PTH receptor agonist.

20. (Withdrawn) The medicament according to claim 13, comprising from 20 to 200 micrograms of the PTH receptor agonist.

21. (New) The method of claim 1 wherein the activation domain is selected from the group consisting of amino acids SVSEIQ, AVSEIQ, or AVSEHQ.

22. (New) The method of claim 1 wherein the receptor binding domain comprises the amino acids selected from the group consisting of LRKKLQDVHNF, LRKKLQDVHNY, LHHLIAEIHTA, LEKLEKLHNF, LRKLLQDLHNF, LHAibLIAEIHTA, LEKLEKLThiTA, LEKLELLHTA, LHHLLAELHTA, LEKLIEKIHTA, or LHHLIAEIHTA.

23. (New) The method of claim 1 wherein the parathyroid hormone receptor agonist is selected from the group consisting of:

SEQIDNO_1	SVSEIQLMHNLGKHLNSMERVEWLRKKLQDVHNF,
SEQIDNO_2	AVSEIQFMHNLGKHLSSMERVEWLRKKLQDVHNF,
SEQIDNO_3	AVSEHQLLHDKGKSIQDLRRRFFLHHLIAEIHTA,
SEQIDNO_4	AVSEIQFXHNLXKHLSSXERVEXLRRKKLQDVHNY,
SEQIDNO_5	SVSEIQLMHNLGKHLNSMERVELLEKLEKLHNF,
SEQIDNO_6	SVSEIQLMHNLGKHLNSMERVEWLEKKLEKVHNF,

SEQIDNO_7	SVSEIQIMHNLGKHLNSMERVELLRKLLQDLHNF,
SEQIDNO_8	AVSEHQLLHDKGKSIQDLRRRFFFLHXLIAEIH7A,
SEQIDNO_9	AVSEHQLLHDKGKSIQDLRRRELEKLEKLEK7A,
SEQIDNO_10	AVSEHQLLHDKGKSIQDLRRRELEKLEKLEL7A,
SEQIDNO_11	AVSEHQLLHDKGKSIQDLRRRFL7LHHL7AEL7A,
SEQIDNO_12	AVSEHQLLHDKGKSIQDLRRREFLEKLEKIEI7A,
SEQIDNO_13	AVSEIQFXHNLGKHLSSXXRVE7LRRKKLQDVHNY,
SEQIDNO_14	AVSEIQFXHNLGKHLSSXXRVE7LRRKKLQDVHNY,
SEQIDNO_15	AVSEIQFXHNLGKHLSSXXRVE7LRRKKLQDVHNY,
SEQIDNO_16	AVSEIQFXHNLGKHLSSXXRVE7LRRKKLQDVHNY,
SEQIDNO_17	AVSEIQFXHNLGKHLSSXXRVE7LRRKKLQDVHNY,
SEQIDNO_18	AVSEIQFMHNLGKHL7SXXRVE7LRRKKLQDVHNF,
SEQIDNO_19	AVSEIQFMHNLGKHL7SXXRVE7LRRKKLQDVHNF,
SEQIDNO_20	AVSEIQFMHNLGKHL7SXXRVE7LRRKKLQDVHNF,
SEQIDNO_21	AVSEIQFMHNLGKHL7SXXRVE7LRRKKLQDVHNF,
SEQIDNO_22	AVSEIQFMHNLGKHL7SXXRVE7LRRKKLQDVHNF,
SEQIDNO_23	AVSEIQFMHNLGKHL7SXXRVE7LRRKKLQDVHNF,
SEQIDNO_24	AVSEIQFMHNLGKHL7SXXRVE7LRRKKLQDVHNF,
SEQIDNO_25	AVSEIQFMHNLGKHL7SXXRVE7LRRKKLQDVHNF,
SEQIDNO_26	AVSEIQFMHNLGKHL7SXXRVE7LRRKKLQDVHNF,
SEQIDNO_27	AVSEIQFMHNLGKHL7SXXRVE7LRRKKLQDVHNF,
SEQIDNO_28	AVSEIQFMHNLGKHL7SXXRVE7LRRKKLQDVHNF,
SEQIDNO_29	AVSEIQFMHNLGKHL7SXXRVE7LRRKKLQDVHNF,
SEQIDNO_30	AVSEIQFMHNLGKHL7SXXRVE7LRRKKLQDVHNF,
SEQIDNO_31	AVSEIQFMHNLGKHL7SXXRVE7LRRKKLQDVHNF,
SEQIDNO_32	AVSEIQFMHNLGKHL7SXXRVE7LRRKKLQDVHNF,
SEQIDNO_33	AVSEIQFMHNLGKHL7SXXRVE7LRRKKLQDVHNF,
SEQIDNO_34	AVSEIQFMHNLGKHL7SXXRVE7LRRKKLQDVHNF,
SEQIDNO_35	AVSEIQFMHNLGKHL7SXXRVE7LRRKKLQDVHNF,
SEQIDNO_36	AVSEIQFMHNLGKHL7SXXRVE7LRRKKLQDVHNF,
SEQIDNO_37	AVSEIQFMHNLGKHL7SXXRVE7LRRKKLQDVHNF,
SEQIDNO_38	AVSEIQFMHNLGKHL7SXXRVE7LRRKKLQDVHNF,
SEQIDNO_39	AVSEIQFMHNLGKHL7SXXRVE7LRRKKLQDVHNF,
SEQIDNO_40	AVSEIQFMHNLGKHL7SXXRVE7LRRKKLQDVHNF,
SEQIDNO_41	AVSEIQFMHNLGKHL7SXXRVE7LRRKKLQDVHNF,
SEQIDNO_42	SVSEIQLXHN7LXKHLNSXERVE7LRRKKLQDVHNY, or
SEQIDNO_43	AVSEHQLLHDKK7SIQDLRRRFFFLHHL7AIEI7A.